Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by laboratory testing of tissue samples
• People who have at least one area of cancer that can be measured on a scan, according to a standard set of measurement rules
• People whose cancer has tested positive for a specific genetic change called a KRAS G12D mutation (a tissue sample is needed for further confirmation testing by the trial laboratory)
• People who are generally well enough to carry out normal daily activities, with little or no limitation (as rated by a standard medical scale)
• People whose liver, kidneys, and other organs are functioning adequately
• For the second-line treatment group: People who have received only one prior treatment for their cancer that has spread to other parts of the body — or whose cancer came back within 6 months of completing an earlier course of treatment after surgery
• For the first-line treatment group: People who have not yet received treatment for cancer that has spread, or who have received no more than one cycle of standard treatment for it

Who may not be able to join:

• People whose cancer has other related genetic mutations (in the same family of mutations as KRAS) in addition to the KRAS G12D mutation
• People who have received any other cancer treatment within 4 weeks before the first trial treatment dose (or within a shorter drug-specific timeframe, whichever comes first)
• People who have had major surgery within 4 weeks before the first trial treatment dose
• People who have had radiation therapy within 1 week before the first trial treatment dose, or radiation to the brain or lungs within 2 weeks before the first trial treatment dose
• People with a history of serious lung inflammation caused by a medication
• People who have previously been treated with a drug that directly targets the RAS protein
• People who have cancer that has spread to the brain and is either untreated or currently causing symptoms
• People who have taken certain medications that strongly affect how the body processes drugs (specific enzyme inhibitors or inducers), or certain other medications with a very narrow safe dosage range, within 14 days before the first trial treatment dose (or within a shorter drug-specific timeframe, whichever comes first)
• People who have taken proton pump inhibitors (such as medications commonly used for heartburn or stomach acid) or a similar type of stomach acid medication within 5 days before the first trial treatment dose
• People who are unable to swallow tablets or capsules
• Additional criteria not listed here may also apply (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.